Volume 9, Issue 1 (2023)
IEM 2023, 9(1): 79-85 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Chidambaram Y, Jenil Dhas C, Abilash N, Petchiappan V, Alagesan M. Thromboembolic Manifestations in Hospitalized COVID-19 Patients in India- A Single-Centre Retrospective Study. IEM 2023; 9 (1) :79-85
URL: http://iem.modares.ac.ir/article-4-65604-en.html
URL: http://iem.modares.ac.ir/article-4-65604-en.html
Yoganathan Chidambaram * 
1, Clement Jenil Dhas2 , Nekkanti Abilash2 , Velammal Petchiappan3 , Murali Alagesan4
1, Clement Jenil Dhas2 , Nekkanti Abilash2 , Velammal Petchiappan3 , Murali Alagesan4
1- Assistant Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India , oganathancc@gmail.com
2- Assistant Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
3- Associate Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
4- Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
2- Assistant Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
3- Associate Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
4- Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India
Abstract: (1094 Views)
Backgrounds: This study aimed to evaluate the incidence and clinical profile of thromboembolic disease in COVID-19 patients and analyze its association with D-dimer and Interleukin (IL)-6 levels.
Materials & Methods: This was a retrospective, single-center study conducted by analyzing data obtained from the case records of COVID-19 confirmed patients with thromboembolic manifestations in India during January 2020 to February 2022. Patients with conditions such as malignancy, prothrombotic states, and autoimmune diseases were excluded from the analysis. D-dimer and IL-6 levels and thrombotic events were analyzed along with comorbid conditions like diabetes mellitus (DM), hypertension, and dyslipidemia. Chi-square tests were used to evaluate the association of various thrombotic manifestations with D-dimer and IL-6 levels. A p-value of ≤ .05 was considered statistically significant.
Findings: The mean age of 88 COVID-19 confirmed cases with thrombotic manifestations was 61.01±15.23 years, and the majority (62.5%) of the cases were male. D-dimer and IL-6 levels were elevated in 78.41 and 80.68% of the cases, respectively. The predominant thrombotic manifestation was pulmonary thromboembolism (PTE) (48.86%), followed by acute coronary syndrome (ACS) (36.36%), cerebrovascular accident (CVA) (22.73%), etc. There was no significant association between various thrombotic manifestations and D-dimer and IL-6 levels.
Conclusion: PTE was the predominant thromboembolic manifestation in COVID-19 patients in the current cohort. Elevated D-dimer and IL-6 levels though found in the majority of the patients were not associated with thrombotic events. However, early recognition and treatment could reduce morbidity in COVID-19 patients.
Materials & Methods: This was a retrospective, single-center study conducted by analyzing data obtained from the case records of COVID-19 confirmed patients with thromboembolic manifestations in India during January 2020 to February 2022. Patients with conditions such as malignancy, prothrombotic states, and autoimmune diseases were excluded from the analysis. D-dimer and IL-6 levels and thrombotic events were analyzed along with comorbid conditions like diabetes mellitus (DM), hypertension, and dyslipidemia. Chi-square tests were used to evaluate the association of various thrombotic manifestations with D-dimer and IL-6 levels. A p-value of ≤ .05 was considered statistically significant.
Findings: The mean age of 88 COVID-19 confirmed cases with thrombotic manifestations was 61.01±15.23 years, and the majority (62.5%) of the cases were male. D-dimer and IL-6 levels were elevated in 78.41 and 80.68% of the cases, respectively. The predominant thrombotic manifestation was pulmonary thromboembolism (PTE) (48.86%), followed by acute coronary syndrome (ACS) (36.36%), cerebrovascular accident (CVA) (22.73%), etc. There was no significant association between various thrombotic manifestations and D-dimer and IL-6 levels.
Conclusion: PTE was the predominant thromboembolic manifestation in COVID-19 patients in the current cohort. Elevated D-dimer and IL-6 levels though found in the majority of the patients were not associated with thrombotic events. However, early recognition and treatment could reduce morbidity in COVID-19 patients.
Article Type: Original Research |
Subject:
Virology
Received: 2022/11/24 | Accepted: 2023/02/27 | Published: 2023/03/10
Received: 2022/11/24 | Accepted: 2023/02/27 | Published: 2023/03/10
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |